FIG. 1



control
DW69N
DW69C
DS84N
S-PT84
DB30N
DB30C
DA74N
DA74C
DS51N
DS51C
DB22N
DB22C
DS25N
DS25C
DS2N
DS2C
0
500
1000
1500
2000
2500
IL12(p70) (pg/ml)

FIG. 2



1000
800
600
400
200
0
IL-12 (p70) (pg/ml)
6 h
0
5
10
15
20
25
Time after administration (h)

FIG. 3



control
DW69N
DW69C
DS84N
S-PT84
DB30N
DB30C
DA74N
DA74C
DS51N
DS51C
DB22N
DB22C
DS25N
DS25C
DS2N
DS2C
**
*
*
0
200
400
600
800
1000
1200
IL-12(p70) (pg/ml)

FIG. 4(a)




FIG. 4(b)




FIG. 4(c)




FIG. 5 (a)




FIG. 5 (b)







FIG. 5 (c)










FIG. 6




FIG. 7(a)



control
B1
B2
B3
B4
14.1%
0.8%
3.2%
E1
E2
E3
E4
10.5%
1.5%
5.1%
CD4+
CD8+
CD69+

FIG. 7(b)



S-PT84
B1
B2
B3
B4
11.6%
1.4%
13.9%
E1
E2
E3
E4
23.4%
7.5%
12.9%
CD4+
CD8+
CD69+

FIG. 8




FIG. 9




FIG. 10




FIG. 11






FIG. 12



* : P<0.05 vs CY+S-PT84+S-PT84

FIG. 13



* : P<0.05 vs Control

FIG. 14





FIG. 15


10
8
6
4
2
0
NK activity (%)
Control
Stress
Stress+S-PT84
**
80:1
40:1
20:1
E:T ratio